Third Arc Bio Debuts with $165M Funding and Former J&J Executives at the Helm

1. Third Arc Bio: A new biotech company co-founded by Sanjaya Singh, former global head of J&J's Janssen Biotherapeutics unit.
2. Funding: The company has debuted with $165 million in funding.
3. Leadership: The company is led by a trio of former J&J executives, including Sanjaya Singh.
4. Focus: Third Arc Bio is focused on developing treatments for cancer and immune diseases.
5. Pipeline: The company has not disclosed details about its pipeline or specific diseases it is targeting.